Smith & Nephew To Set Up Factory In Suzhou Industrial Park
This article was originally published in PharmAsia News
Smith & Nephew recently held a groundbreaking ceremony for its first factory in China at the Suzhou Industrial Park. With an initial investment of $80 million, the plant will mainly produce medical devices that will be supplied to 65 countries across the world. Smith & Nephew officials said Suzhou Industrial Park was chosen because of its first-class environment and facilities as well as enterprising atmosphere. To date, the park has attracted health care MNCs such as GSK, Eli Lilly, Eisai, Baxter, Herbalife and Johnson & Johnson, with total investment surpassing $1 billion. (Click here for more - Chinese Language)
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.